Biblio

Export 282 results:
Author Title Type Year
Filters: First Letter Of Keyword is T  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Tandem Mass Spectrometry
D. Jigar Shah, Rohlfing, F., Anand, S., W Johnson, E., Alvarez, M. H. Tanielle B., Cobell, J., King, J., Young, S. A., Kauwe, J. S. K., and Graves, S. W., “Discovery and Subsequent Confirmation of Novel Serum Biomarkers Diagnosing Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 2, pp. 317-27, 2016.
B. Gurel, Cansev, M., Sevinc, C., Kelestemur, S., Ocalan, B., Cakir, A., Aydin, S., Kahveci, N., Ozansoy, M., Taskapilioglu, O., Ulus, I. Hakki, Başar, M. Karayel, Sahin, B., Tuzuner, M. Bora, and Baykal, A. Tarik, “Early Stage Alterations in CA1 Extracellular Region Proteins Indicate Dysregulation of IL6 and Iron Homeostasis in the 5XFAD Alzheimer's Disease Mouse Model.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1399-1410, 2018.
J. Bastrup, Hansen, K. H., Poulsen, T. B. G., Kastaniegaard, K., Asuni, A. A., Christensen, S., Belling, D., Helboe, L., Stensballe, A., and Volbracht, C., “Anti-Aβ Antibody Aducanumab Regulates the Proteome of Senile Plaques and Closely Surrounding Tissue in a Transgenic Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 79, no. 1, pp. 249-265, 2021.
Task Performance and Analysis
A. Synn, Mothakunnel, A., Kumfor, F., Chen, Y., Piguet, O., Hodges, J. R., and Irish, M., “Mental States in Moving Shapes: Distinct Cortical and Subcortical Contributions to Theory of Mind Impairments in Dementia.”, J Alzheimers Dis, vol. 61, no. 2, pp. 521-535, 2018.
tau Proteins
A. Koppara, Wolfsgruber, S., Kleineidam, L., Schmidtke, K., Frölich, L., Kurz, A., Schulz, S., Hampel, H., Heuser, I., Peters, O., Reischies, F. M., Jahn, H., Luckhaus, C., Hüll, M., Gertz, H. - J., Schröder, J., Pantel, J., Rienhoff, O., Rüther, E., Henn, F., Wiltfang, J., Maier, W., Jessen, F., Kornhuber, J., and Wagner, M., “The Latent Dementia Phenotype δ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 49, no. 2, pp. 547-60, 2016.
C. R. Jack, Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., Lesnick, T. G., Pankratz, V. S., Donohue, M. C., and Trojanowski, J. Q., “Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.”, Lancet Neurol, vol. 12, no. 2, pp. 207-16, 2013.
A. de Calignon, Polydoro, M., Suárez-Calvet, M., William, C., Adamowicz, D. H., Kopeikina, K. J., Pitstick, R., Sahara, N., Ashe, K. H., Carlson, G. A., Spires-Jones, T. L., and Hyman, B. T., “Propagation of tau pathology in a model of early Alzheimer's disease.”, Neuron, vol. 73, no. 4, pp. 685-97, 2012.
J. C. Morris, Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., and Mintun, M. A., “APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.”, Ann Neurol, vol. 67, no. 1, pp. 122-31, 2010.
M. Jin, Shepardson, N., Yang, T., Chen, G., Walsh, D., and Selkoe, D. J., “Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration.”, Proc Natl Acad Sci U S A, vol. 108, no. 14, pp. 5819-24, 2011.
M. Jucker and Walker, L. C., “Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders.”, Ann Neurol, vol. 70, no. 4, pp. 532-40, 2011.
K. Iqbal, Liu, F., Gong, C. - X., and Grundke-Iqbal, I., “Tau in Alzheimer disease and related tauopathies.”, Curr Alzheimer Res, vol. 7, no. 8, pp. 656-64, 2010.
M. Bolós, Llorens-Martín, M., Jurado-Arjona, J., Hernández, F., Rábano, A., and Avila, J., “Direct Evidence of Internalization of Tau by Microglia In Vitro and In Vivo.”, J Alzheimers Dis, vol. 50, no. 1, pp. 77-87, 2016.
A. Ezra, Rabinovich-Nikitin, I., Rabinovich-Toidman, P., and Solomon, B., “Multifunctional Effect of Human Serum Albumin Reduces Alzheimer's Disease Related Pathologies in the 3xTg Mouse Model.”, J Alzheimers Dis, vol. 50, no. 1, pp. 175-88, 2016.
S. Hoon Choi, Kim, Y. Hye, Hebisch, M., Sliwinski, C., Lee, S., D'Avanzo, C., Chen, H., Hooli, B., Asselin, C., Muffat, J., Klee, J. B., Zhang, C., Wainger, B. J., Peitz, M., Kovacs, D. M., Woolf, C. J., Wagner, S. L., Tanzi, R. E., and Kim, D. Yeon, “A three-dimensional human neural cell culture model of Alzheimer's disease.”, Nature, vol. 515, no. 7526, pp. 274-8, 2014.
S. Salloway, Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. Cristina, Liu, E., Grundman, M., Yuen, E., Black, R., and H Brashear, R., “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R., “Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
P. Buchhave, Minthon, L., Zetterberg, H., Wallin, A. K., Blennow, K., and Hansson, O., “Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.”, Arch Gen Psychiatry, vol. 69, no. 1, pp. 98-106, 2012.
H. Braak, Thal, D. R., Ghebremedhin, E., and Del Tredici, K., “Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years.”, J Neuropathol Exp Neurol, vol. 70, no. 11, pp. 960-9, 2011.
C. R. Jack, Vemuri, P., Wiste, H. J., Weigand, S. D., Aisen, P. S., Trojanowski, J. Q., Shaw, L. M., Bernstein, M. A., Petersen, R. C., Weiner, M. W., and Knopman, D. S., “Evidence for ordering of Alzheimer disease biomarkers.”, Arch Neurol, vol. 68, no. 12, pp. 1526-35, 2011.
M. T. Fodero-Tavoletti, Okamura, N., Furumoto, S., Mulligan, R. S., Connor, A. R., McLean, C. A., Cao, D., Rigopoulos, A., Cartwright, G. A., O'Keefe, G., Gong, S., Adlard, P. A., Barnham, K. J., Rowe, C. C., Masters, C. L., Kudo, Y., Cappai, R., Yanai, K., and Villemagne, V. L., “18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease.”, Brain, vol. 134, no. Pt 4, pp. 1089-100, 2011.
M. Babić Leko, Borovečki, F., Dejanović, N., Hof, P. R., and Šimić, G., “Predictive Value of Cerebrospinal Fluid Visinin-Like Protein-1 Levels for Alzheimer's Disease Early Detection and Differential Diagnosis in Patients with Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 50, no. 3, pp. 765-78, 2016.
R. Smith, Wibom, M., Olsson, T., Hägerström, D., Jögi, J., Rabinovici, G. D., and Hansson, O., “Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation.”, J Alzheimers Dis, vol. 51, no. 2, pp. 339-43, 2016.
F. Piazza, Greenberg, S. M., Savoiardo, M., Gardinetti, M., Chiapparini, L., Raicher, I., Nitrini, R., Sakaguchi, H., Brioschi, M., Billo, G., Colombo, A., Lanzani, F., Piscosquito, G., Carriero, M. Rita, Giaccone, G., Tagliavini, F., Ferrarese, C., and DiFrancesco, J. C., “Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies.”, Ann Neurol, vol. 73, no. 4, pp. 449-58, 2013.
O. Bousiges, Cretin, B., Lavaux, T., Philippi, N., Jung, B., Hezard, S., Heitz, C., Demuynck, C., Gabel, A., Martin-Hunyadi, C., and Blanc, F., “Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1069-83, 2016.
M. Xie, Han, Y., Yu, Q., Wang, X., Wang, S., and Liao, X., “UCH-L1 Inhibition Decreases the Microtubule-Binding Function of Tau Protein.”, J Alzheimers Dis, vol. 49, no. 2, pp. 353-63, 2016.

Pages